New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the...
Year Data Published Urologic Oncology Validates Adverse Pathology Prostate Cancer Outcomes Clinically Low Risk Patients Exact Sciences Corp
Source: prnewswire.com